Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > A/O Sept. 08th ONCY's cash runway is until late Q4, 2024

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 09, 2023 4:00pm

255 Views

Post# 35627852

RE:RE:RE:RE:RE:A/O Sept. 08th ONCY's cash runway is until late Q4, 2024

The Phase 2 GOBLET-1 study also trialed a pancreatic cancer cohort. Goblet could be the basis of an Accelerated Approval filing with the FDA and the Phase 3 PanCan clinical study would serve as the confirmatory study that FDA would then check off as the met requirement in their accelerated approval of pelareorep in this indication.

<< Previous

Bullboard Posts

Next >>

Rich TV Live's Stocks to Watch this week (Nov. 22, 2024)